Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients by van den Elsen, Simone H J et al.
  
 University of Groningen
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for
Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients
van den Elsen, Simone H J; Sturkenboom, Marieke G G; Akkerman, Onno W; Manika,
Katerina; Kioumis, Ioannis P; van der Werf, Tjip S; Johnson, John L; Peloquin, Charles;
Touw, Daan J; Alffenaar, Jan-Willem C
Published in:
Antimicrobial Agents and Chemotherapy
DOI:
10.1128/AAC.00384-19
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van den Elsen, S. H. J., Sturkenboom, M. G. G., Akkerman, O. W., Manika, K., Kioumis, I. P., van der Werf,
T. S., ... Alffenaar, J-W. C. (2019). Limited Sampling Strategies Using Linear Regression and the Bayesian
Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial Agents
and Chemotherapy, 63(7), [ARTN e00384-19]. https://doi.org/10.1128/AAC.00384-19
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug 1 
monitoring of moxifloxacin in tuberculosis patients 2 
 3 
Simone HJ van den Elsena, Marieke GG Sturkenbooma, Onno W Akkermanb,c, Katerina Manikad, Ioannis P 4 
Kioumisd, Tjip S van der Werfb,e, John L Johnsonf, Charles Peloquing, Daan J Touwa, Jan-Willem C 5 
Alffenaara,h# 6 
 7 
a University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and 8 
Pharmacology, Groningen, The Netherlands 9 
b University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and 10 
Tuberculosis, Groningen, The Netherlands 11 
c University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, 12 
The Netherlands. 13 
d Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, G. 14 
Papanikolaou Hospital, Thessaloniki, Greece 15 
e University of Groningen, University Medical Center Groningen, Department of Internal Medicine, 16 
Groningen, The Netherlands 17 
f Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University 18 
Hospitals Cleveland Medical Center, Cleveland, OH, USA 19 
g Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, University of Florida, Gainesville, 20 
FL, USA 21 
h University of Sydney, faculty of Medicine and Health, School of Pharmacy and Westmead hospital, 22 
Sydney, Australia 23 
 24 
AAC Accepted Manuscript Posted Online 22 April 2019
Antimicrob. Agents Chemother. doi:10.1128/AAC.00384-19














# Corresponding author:  J.W.C. Alffenaar, University Medical Center Groningen, Department of Clinical 26 




Running title: Limited Sampling Strategies for TDM of Moxifloxacin 31 
 32 
Funding: No funding was received for the current study. The Brazilian TBRU moxifloxacin study was 33 
funded by the US National Institutes of Health (NO1-AI95383 and HHSN266200700022C). 34 
Conflicts of interest: none 35 















Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve response to 39 
tuberculosis treatment and reduce acquired drug resistance. Limited sampling strategies (LSSs) are able 40 
to reduce the burden of TDM by using a small number of appropriately timed samples to estimate the 41 
parameter of interest; the area under the concentration time curve. This study aimed to develop LSSs for 42 
moxifloxacin alone (MFX) and together with rifampicin (MFX+RIF) in TB patients.  43 
Population pharmacokinetic (popPK) models were developed for MFX (n=77) and MFX+RIF (n=24). 44 
Additionally, LSSs using Bayesian approach and multiple linear regression were developed. Jackknife 45 
analysis was used for internal validation of the popPK models and multiple linear regression LSSs. 46 
Clinically feasible LSSs (1-3 samples; 6 h timespan post-dose; 1 h interval) were tested.  47 
Moxifloxacin exposure was slightly underestimated in the one compartment models of MFX (mean -48 
5.1%, standard error [SE] 0.8%) and MFX+RIF (mean -10%, SE 2.5%). The Bayesian LSSs for MFX and 49 
MFX+RIF (both 0 and 6 h) slightly underestimated drug exposure (MFX mean -4.8%, SE 1.3%; MFX+RIF 50 
mean -5.5%, SE 3.1%). The multiple linear regression LSS for MFX (0 and 4 h) and MFX+RIF (1 and 6 h), 51 
showed a mean overestimation of 0.2% (SE 1.3%) and 0.9% (SE 2.1%), respectively. 52 
LSSs were successfully developed using the Bayesian approach (MFX and MFX+RIF; 0 and 6 h) and 53 
multiple linear regression (MFX 0 and 4 h, MFX+RIF 1 and 6 h). These LSSs can be implemented in clinical 54 














Each year, the global tuberculosis (TB) incidence declines with approximately 2%, while by 2020 an 57 
annual 4-5% decline is strived for by the World Health Organization (WHO).(1) Multidrug-resistant TB 58 
(MDR-TB) remains a major problem with an estimated number of 458,000 cases in 2017.(1) Currently, 59 
the worldwide success rate of MDR-TB treatment is 55% and this is considered low when compared to a 60 
success rate of 85% for drug-susceptible TB (DS-TB).(1)  61 
Moxifloxacin, a fluoroquinolone, is one of the most important drugs for the treatment of MDR-TB(2), but 62 
has also been used as an alternative to first-line anti-TB drugs if not well tolerated or suggested to 63 
include in case of isoniazid resistance.(3–5) In general, the toxicity profile of moxifloxacin is rather mild, 64 
though it includes concentration dependent QTc interval prolongation and, rarely, tendinopathy.(6–9) A 65 
clinically relevant drug-drug interaction is the combination of moxifloxacin with rifampicin, since these 66 
two drugs can be used concomitantly in TB treatment. Rifampicin lowers the moxifloxacin area under the 67 
concentration-time curve of 0-24 h (AUC0-24) with approximately 30% by inducing phase II metabolising 68 
enzymes (glucuronosyltransferase and sulphotransferase).(10–12) 69 
The efficacy of fluoroquinolones is related to the ratio of AUC0-24 to minimal inhibitory concentration 70 
(AUC0-24/MIC).(13, 14) The fluoroquinolone exposure is effective against gram-negative bacteria at an 71 
AUC0-24/MIC >100-125 and against gram-positive species at an AUC0-24/MIC >25-30.(13, 15, 16) An in vitro 72 
moxifloxacin exposure of unbound (f)AUC0-24/MIC of >53 was able to substantially decrease the total 73 
population of M. tuberculosis with over 3 log10 CFU/ml as well as suppress emergence of drug resistance, 74 
while an fAUC0-24/MIC >102 completely killed the fluoroquinolone sensitive population of M. tuberculosis 75 
without observing development of drug resistance.(17) Approximately 50% of moxifloxacin is assumed to 76 
be protein bound, although protein binding is highly variable between individuals and might be 77 
concentration dependent.(13, 16, 18, 19) Corresponding with fAUC0-24/MIC>53 and a fraction unbound 78 













individual data of protein binding is often lacking.(18, 20, 21) In case of a proven susceptibility for 80 
moxifloxacin while lacking a MIC value of the strain, the target AUC0-24 is generally set at >50-65 mg∙h/L 81 
based on a critical concentration of 0.5 mg/L.(22, 23) 82 
Therapeutic drug monitoring (TDM) is recommended by the American Thoracic Society for all second-line 83 
drugs, including moxifloxacin.(24, 25) It is important to monitor the moxifloxacin exposure in TB patients 84 
to determine an individualized dose, because of substantial inter-individual pharmacokinetic variability 85 
and relevant drug-drug interactions with the risk of treatment failure and developing drug resistance.(18, 86 
26–28) However, routine TDM to estimate AUC0-24 requiring frequent blood sampling is time-consuming, 87 
a burden for patients and health care professionals, and expensive. Optimising the sampling schedule by 88 
developing a limited sampling strategy (LSS) could overcome these difficulties with TDM in TB 89 
treatment.(29)  90 
There are two main methods to develop a LSS; the Bayesian approach and multiple linear regression.(30) 91 
The advantages of the Bayesian approach are the flexible timing of samples as the population 92 
pharmacokinetic model can correct for deviations and that it takes a number of parameters into account 93 
for example sex, age, and kidney function, leading to a more accurate estimation of AUC0-24. The 94 
advantage of multiple linear regression-based LSSs is that these do not require modelling software and 95 
AUC0-24 can be easily estimated using only an equation and the measurement of drug concentrations. 96 
The disadvantage is that samples must be taken exactly according to the predefined schedule and the 97 
population of interest should be comparable because patient characteristics are not included in the 98 
equations to estimate drug exposure.(30) 99 
Pranger et al described a LSS for moxifloxacin for the first time using t=4 and 14 h post-dose samples.(21) 100 
This sampling strategy can be considered unpractical to be used in daily practice. Magis-Escurra et al 101 
described LSSs to simultaneously estimate AUC0-24 of all first-line drugs together with moxifloxacin (t=1, 102 













moxifloxacin in combination with rifampicin.(20) Therefore the influence of the drug-drug interaction 104 
between moxifloxacin and rifampicin, namely an increased moxifloxacin clearance, was not taken into 105 
account in these LSSs.  106 
Therefore, the aim of this study was to develop and validate two population pharmacokinetic models of 107 
moxifloxacin (alone and with rifampicin) along with clinically feasible LSSs using the Bayesian approach 108 




Study population 113 
The group with moxifloxacin alone (MFX) included pharmacokinetic profiles of 77 TB patients and the 114 
group with moxifloxacin together with rifampicin (MFX+RIF) included profiles of 24 TB patients (Figure 115 
1). The baseline characteristics sex, age and height were significantly different (P<0.05) between these 116 
two groups (Table 1). Additionally, the AUC0-24 calculated with the trapezoidal rule (AUC0-24, ref) was 117 
significantly lower and time of peak concentration (Tmax) was significantly earlier in the MFX+RIF group 118 
(P<0.05, Table 2). Several abnormal pharmacokinetic curves (e.g. delayed absorption or single aberrant 119 
data point) were observed in both the MFX and MFX+RIF group. 120 
 121 
Population pharmacokinetic model 122 
For both MFX and MFX+RIF, an one compartment model with lag time resulted in the lowest Akaike 123 
Information Criterion (AIC) values and described the data best (Table 3). Two compartment models were 124 
not favourable for either MFX or MFX+RIF. A statistical comparison of the pharmacokinetic parameters 125 
of the MFX versus MFX+RIF model was provided in Table 4. Total body clearance (CL) was higher and lag 126 













mean underestimation of AUC0-24 of 5.1% (standard error (SE) 0.8%) in the MFX model and a mean 128 
underestimation of 10% (SE 2.5%) in the MFX+RIF model (Figure 2A and Figure 3A). In the validation of 129 
the MFX model, an r2 of 0.98, y-axis intercept of -0.3 (95% CI -1.1 to 0.5), and slope of 0.96 (95% CI 0.94-130 
0.98) was found in the Passing Bablok regression (Figure 2B). For the MFX+RIF model, an r2 of 0.94, y-axis 131 
intercept of -1.0 (95% CI -4.1 to 0.9), and slope of 0.98 (95% CI 0.92-1.07) was found in the Passing 132 
Bablok regression (Figure 3B). 133 
 134 
LSS using the Bayesian approach 135 
The best performing LSSs of MFX and MFX+RIF are shown in Table 5 and Table 6, including mean 136 
prediction error (MPE), root mean squared error (RMSE), and r2 to evaluate the performance of the LSSs. 137 
The performance of the LSS using t=2 and 6 h samples was evaluated as well, because this strategy is 138 
currently used in many health facilities for TDM of anti-TB drugs.(31) Not all strategies met the pre-set 139 
acceptance criteria (RMSE<15%, MPE<5%).(21) Low r2 values were observed which were caused by high 140 
interindividual variability in performance of the LSSs.   141 
For the MFX model, an LSS using t=0 and 6 h samples was chosen for further evaluation (RSME=15.17%, 142 
MPE= 2.42%, r2=0.874), because it required one sample less than the three-sample strategies, while 143 
RMSE was only slightly above 15%. The internal validation showed a mean underestimation of 4.8% (SE 144 
1.3%). However, low AUC0-24 values were more frequently overestimated in contrast to AUC0-24 >40 145 
mg*h/L mainly being underestimated by the LSS (Figure 4A). The Passing Bablok regression showed an r2 146 
of 0.94, y-axis intercept of 3.4 (95% CI 1.6-4.9), and slope of 0.85 (95% CI 0.80-0.91) (Figure 4B).  147 
For the MFX+RIF model, an LSS using t=0 h and 6 h samples was chosen for further evaluation 148 
(RSME=15.81%, MPE= 2.35%, r2=0.885), because of the benefit of requiring only 2 samples while 149 













underestimation of 5.5% (SE 3.1%) in the Bland-Altman plot and an r2 of 0.90, y-axis intercept of -1.3 151 
(95% CI -4.4 to 2.8), and slope of 1.0 (95% CI 0.88-1.10) in the Passing Bablok regression (Figure 5).  152 
 153 
LSS using multiple linear regression 154 
Table 7 and Table 8 show the best performing LSSs for MFX and MFX+RIF. The performance of the 155 
frequently used LSS using t=2 and 6 h samples was evaluated as well and included in the tables. None of 156 
the MFX LSSs met the acceptance criteria (RMSE<15%, MPE<5%) as bias was above 5% for all 157 
combinations. For MFX+RIF, the two three-sample strategies and LSS using t=1 and 6 h samples met the 158 
acceptance criteria.  159 
The MFX LSS using t=0 and 4 h samples (RSME=9.25%, MPE= 6.85%, r2=0.957) had a comparable 160 
performance to the three-sample strategies while being more clinically feasible and therefore was 161 
chosen for further evaluation. In contrast to the Bayesian LSSs for MFX and MFX+RIF, a t=0 and 6 h 162 
strategy was not feasible using a multiple linear regression approach as its performance was 163 
substantially worse (RMSE=12.01, MPE=9.43, r2=0.905) than the LSS using t=0 and 4 h samples. Internal 164 
validation of this t=0 and 4 h LSS for MFX showed a mean overestimation of 0.2% (SE 1.3%) in the Bland-165 
Altman plot and an r2 of 0.95, y-axis intercept of 0.1 (95% CI -2.1 to 1.6), and slope of 0.99 (95% CI 0.95-166 
1.06) in the Passing Bablok regression (Figure 6).  167 
For MFX+RIF, the LSS using t=1 and 6 h samples (RSME=6.09%, MPE= 4.83%, r2=0.971) was chosen for 168 
further evaluation, because of clinical suitability in addition to good performance (RMSE<15%, MPE<5%). 169 
Internal validation showed a mean overestimation of 0.9% (SE 2.1%) in the Bland-Altman plot and an r2 170 
of 0.96, y-axis intercept of -0.2 (95% CI -4.9 to 2.3), and slope of 1.02 (95% CI 0.88-1.15) in the Passing 171 















In this study, we successfully developed a population pharmacokinetic model for moxifloxacin alone and 175 
in combination with rifampicin. Furthermore, we developed and validated sampling strategies using the 176 
Bayesian approach (MFX and MFX+RIF t=0 and 6 h) and multiple linear regression (MFX t=0 and 4 h; 177 
MFX+RIF t=1 and 6 h) for both groups as well.  178 
It was decided to develop two separate population pharmacokinetic models, and therefore also separate 179 
LSSs, for moxifloxacin alone and in combination with rifampicin after observing a significant effect of 180 
rifampicin on the pharmacokinetics of moxifloxacin. The population pharmacokinetic model of MFX+RIF 181 
showed an approximately 35% higher total body clearance of moxifloxacin when compared to the MFX 182 
pharmacokinetic model (Table 4). This was to be expected as rifampicin enhances metabolism of 183 
moxifloxacin and increases in total body clearance of 45-50% have been reported by others.(10, 32) As a 184 
result of this drug-drug interaction, pharmacokinetic profiles of MFX+RIF showed reduced moxifloxacin 185 
concentrations and 25% lower median moxifloxacin AUC0-24 values after administration of a similar dose 186 
(Figure 1, Table 2). The latter is confirmed by a significant -17% difference in dose-corrected AUC0-24,ref 187 
between the MFX and MFX+RIF group (Table 2). The decrease in moxifloxacin exposure by rifampicin was 188 
estimated at 30% in previous studies (10, 12, 32), although others found non-significant or smaller 189 
decreases in moxifloxacin AUC0-24.(21, 33) In this study we observed only a slightly smaller effect of 190 
rifampicin on the total body clearance and exposure than previously reported. This might be explained 191 
by the possibility that maximal enzyme induction was not achieved yet at the moment of sampling in a 192 
few cases, since it generally takes around 10-14 days of rifampicin treatment to reach maximal 193 
induction.(34) Furthermore, we encountered a significant, but small, difference in lag time between the 194 
MFX and MFX+RIF models and in Tmax of the included pharmacokinetic profiles.  The faster absorption of 195 
moxifloxacin in combination rifampicin was found in other studies as well, however some reported the 196 













likely by other differences between the MFX and MFX+RIF group such as concomitantly taken TB drugs 198 
or inter-individual differences in absorption due to disease state. 199 
In addition to the population pharmacokinetic models, we developed and validated LSSs using the 200 
Bayesian approach as well as multiple linear regression for MFX and MFX+RIF. LSSs of moxifloxacin have 201 
been described before. Pranger et al  found a Bayesian LSS with a comparable performance (RMSE=15%, 202 
MPE=-1.5%, r2=0.90) when compared to our LSSs for MFX and MFX+RIF.(21) The LSS of Magis-Escurra et 203 
al performed  better (RMSE=1.45%, MPE=0.58%, r2=0.9935) than the multiple linear regression LSSs 204 
proposed in this study.(20) However, a smaller sample size (n=12) was used to establish the equation 205 
and this was not externally validated. Further, we provided suitable sampling strategies for multiple 206 
situations; in patients using moxifloxacin alone or together with rifampicin and for centres that either do 207 
or do not have pharmacokinetic modelling software available. Health care professionals may select the 208 
LSS that is the most applicable to the circumstances.  209 
The Bayesian LSS for MFX (t=0 and 6 h) showed a slight downward trend between the bias of the 210 
estimated AUC0-24 and the mean of the estimated and actual AUC0-24 (Figure 4). Low AUC0-24 values were 211 
more frequently overestimated in comparison to higher AUC0-24 values. A possible cause might be that 212 
we could not differentiate between metabolic clearance and renal clearance in both population 213 
pharmacokinetic models due to a small range of creatinine clearance in the study population. A relatively 214 
high exposure of moxifloxacin in patients with renal insufficiency could be underestimated as renal 215 
function may be overestimated and the other way around for patients with normal renal function and 216 
relatively low exposures. The pharmacokinetic modelling software will fit a curve with the greatest 217 
likelihood of being the actual pharmacokinetic curve based on drug concentrations at 0 and 6 h together 218 
with patient characteristics and data of the entire population. However, when influence of creatinine 219 
clearance is not available the software will pick a fit with average parameters, causing overestimation in 220 













performing three-sample strategies from Table 5, since we focussed on developing a clinically feasible 222 
LSS with a strong preference for only 2 samples. Furthermore, we aimed to provide a simple and well 223 
performing alternative LSS for MFX using multiple linear regression (t=0 and 4 h). We recommend to use 224 
this LSS instead of the Bayesian LSS for MFX, particularly when low drug exposure is suspected, because 225 
overestimation of AUC0-24 can lead to sub therapeutic dosing with treatment failure and acquired drug 226 
resistance as possible harmful consequence.(26, 36, 37) 227 
In this study we decided to validate one LSS for each situation (Bayesian or multiple linear regression; 228 
MFX or MFX+RIF), due to the significant influence of rifampicin on the pharmacokinetics of moxifloxacin 229 
and so there would be a suitable LSS for every patient in each health care centre. The LSSs using multiple 230 
linear regression performed rather well in our study population, but is less flexible in patients with 231 
different characteristics. A Bayesian LSS is therefore preferred for patients who are not comparable to 232 
our study populations as the population pharmacokinetic model is able to include some patient 233 
characteristics. Clinicians are guided to the best option for TDM of moxifloxacin by following the decision 234 
tree in Figure 8. For implementation of moxifloxacin TDM using LSSs in daily practice, it would be 235 
convenient to be able to use one sampling strategy for both MFX and MFX+RIF. This study showed that it 236 
is possible to use t=0 and 6 h samples in a Bayesian LSS for both MFX as well as MFX+RIF and probably 237 
even in a multiple linear regression LSS for MFX+RIF after successful validation. Unfortunately, a multiple 238 
linear regression strategy for MFX alone using t=0 and 6 h samples was not feasible because of inferior 239 
performance. Considering that TB patients are treated with a combination of multiple anti-TB drugs, one 240 
single LSS suitable for all drugs of interest is the ideal situation, but unfortunately also rather challenging 241 
due to the various pharmacokinetic properties of the different drugs. Others did succeed in developing a 242 
LSS using multiple linear regression for simultaneously estimating exposure of all first-line drugs and 243 
moxifloxacin in a small population of TB patients.(20) A 2 and 6 h post-dose sampling strategy is 244 













delayed absorption.(31) However, better performances were found for the LSSs proposed in this study, 246 
although the 2 and 6 h LSS performed within acceptable limits as well in the Bayesian approach and the 247 
multiple linear regression.  248 
In general, we noticed large inter-individual pharmacokinetic variation in terms of moxifloxacin 249 
concentrations (Figure 1), Cmax, and AUC0-24 (Table 2) as described earlier,(18) but also in Ka and CL/F 250 
(Table 4). Patients received 400, 600, or 800 mg moxifloxacin; this obviously influenced drug 251 
concentration, Cmax, and AUC0-24, but not all variation could be explained by different dosage regimes. For 252 
MFX, AUC0-24 corrected to a 400 mg standard dose was ranged from 10.2 to 79.1 mg*h/L and for 253 
MFX+RIF a range of 10.0 to 47.4 mg*h/L. This substantial inter-individual variation is the reason why 254 
TDM of moxifloxacin is helpful to assure optimal drug exposure and thus minimize the risk of treatment 255 
failure and developing acquired drug resistance.(26, 27) The estimated AUC0-24 using one of the LSS 256 
proposed together with the MIC of the M. tuberculosis strain will provide valuable information on the 257 
optimal moxifloxacin dose to be used in an individual patient.  258 
A limitation to the study is the exclusion of the creatinine clearance from the population 259 
pharmacokinetic model. As discussed earlier, this could have led to the observed bias in the MFX LSS 260 
using 0 and 6 h samples as approximately 20% of moxifloxacin is eliminated unchanged in the urine. On 261 
the contrary, a well performing LSS using multiple linear regression (t=0 and 4 h) is a suitable alternative 262 
for MFX. The lack of prospective or external validation of the population pharmacokinetic model and 263 
LSSs could be considered as another limitation. However, we were able to collect a large dataset to 264 
develop the model and clinically feasible LSSs using a sufficient number of pharmacokinetic profiles. A 265 
strength of our study was that a large part of our dataset consisted of drug concentrations which were 266 
collected as part of daily routine TDM. During visual check of the data we noticed several abnormal 267 
curves (both MFX and MFX+RIF) that for instance showed delayed absorption with Tmax values of 4-6 h. 268 













this delayed absorption. In most cases, the subsequent decision to either increase the dose or not was 270 
similar. For these reasons, we expect the results as reported in this study to represent the clinical 271 
practice of TDM using these LSSs very closely. The small sample size of the MFX+RIF group can be 272 
considered as a limitation as well, although comparable to previously published LSS studies.(21, 38–41) 273 
We consider this sample size as sufficient for exploratory objectives, since this is the first study that 274 
developed separate LSSs for moxifloxacin alone and in combination with rifampicin. Future research can 275 
build on the results described in this study.  276 
In conclusion, we developed and validated two separate pharmacokinetic models for moxifloxacin alone 277 
and in combination with rifampicin in TB patients. We provided data to show significant differences in 278 
drug clearance and drug exposure between these groups. Furthermore, we developed and validated LSS 279 
based on the Bayesian approach (MFX and MFX+RIF 0 and 6 h) and multiple linear regression (MFX 0 and 280 
4 h; MFX+RIF 1 and 6 h) that can be used to perform TDM on moxifloxacin in TB patients. 281 
 282 
Materials and methods 283 
Study population 284 
This study used three databases. Database 1 consisted of retrospective data of routine TDM in 67 285 
tuberculosis patients treated at Tuberculosis Center Beatrixoord, University Medical Center Groningen, 286 
The Netherlands and was collected between January 2006 and May 2017, partly published earlier.(18) All 287 
patients received moxifloxacin (with or without rifampicin) as part of their daily TB treatment and 288 
pharmacokinetic curves were obtained as part of routine TDM care. Each patient was only included once. 289 
Varying sampling schedules were used, but most profiles included t=0, and 1, 2, 3, 4, and 8 h post-dose 290 
samples. Pharmacokinetic profiles consisting of less than 3 data points were excluded. The second 291 
database included data of 25 TB patients participating in a clinical study in Thessaloniki, Greece.(33) 292 













collected at t=0, and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 h after drug intake. The third database consisted of 294 
pharmacokinetic data of 9 Brazilian TB patients receiving 400 mg moxifloxacin (no rifampicin) daily in an 295 
early bactericidal activity study.(14) At the fifth day, blood samples were collected at t=0, and 1, 2, 4, 8, 296 
12, 18 and 24 h after drug intake.  297 
As steady state is reached within 3-5 days of treatment with moxifloxacin, all data was collected during 298 
steady state conditions.(11) In general, no informed consent was required, due to the retrospective 299 
nature of the study.  300 
The total study population was split in two groups; patients that received moxifloxacin alone (MFX) and 301 
patients that received moxifloxacin together with rifampicin (MFX+RIF), because of the pharmacokinetic 302 
drug-drug interaction between rifampicin and moxifloxacin.(10) As sample collection in the MFX+RIF 303 
group was performed after a median number of days on rifampicin treatment of 35 (IQR 13-87), 304 
maximum enzyme induction by rifampicin was expected to be reached in most patients.(35) 305 
Patient characteristics of both groups were tested for significant differences, median (interquartile range 306 
(IQR)) using the Mann-Whitney U test and n (%) using the Fisher’s exact test in IBM SPS Statistics (23, 307 
IBM Corp., Armonk, NY). P values <0.05 were considered significant. 308 
 309 
Population pharmacokinetic model 310 
For each group, MFX and MFX+RIF, a population pharmacokinetic model was developed using the 311 
iterative two-stage Bayesian procedure of the KinPop module of MWPharm (version 3.82, Mediware, 312 
The Netherlands). As the pharmacokinetics of moxifloxacin have been described with one compartment 313 
(14, 21) as well as two-compartment models (42, 43), both types were evaluated. The population 314 
pharmacokinetic parameters of the models were assumed to be log normally distributed with a residual 315 
error and concentration dependent standard deviation (SD=0.1+0.1*C, where C is the moxifloxacin 316 













pharmacokinetic data following intravenous administration was not available, F was fixed at 1 in the 318 
analysis and pharmacokinetic parameters are presented relative to F. Moxifloxacin is mainly metabolised 319 
in the liver by glucuronosyltransferase and sulfotransferase (approximately 80%).(11) Only total body 320 
clearance (CL), the sum of metabolic and renal clearance, was included in the model development, 321 
because it was not possible to determine renal clearance due to a small range of creatinine clearance 322 
values in our dataset.  323 
We started the analysis with a single default one compartment model for both MFX and MFX+RIF 324 
developed by Pranger et al using a very similar methodology.(21) This study found comparable 325 
pharmacokinetic parameters of MFX and MFX+RIF, although likely due to a small sample size. Two 326 
default two compartment models were used, one for MFX and one for MFX+RIF.(42, 44) Modelling was 327 
started with all parameters fixed and Akaike Information Criterion (AIC) was used to evaluate the 328 
model.(45) Subsequently, one by one parameters were Bayesian estimated and each step was evaluated 329 
by calculation of the AIC. A reduction of the AIC with at least 3 points was regarded as a significant 330 
improvement of the model.(46) One compartment models included the parameters CL, volume of 331 
distribution (V), and absorption rate constant (Ka). Two compartment models included the parameters 332 
Ka, CL, inter-compartmental clearance (CL12), central volume of distribution (V1), volume of distribution of 333 
the second compartment (V2), and lag time for absorption (Tlag). Afterwards, Tlag was added to the best 334 
performing one compartment model and evaluated for goodness of fit as well, because of oral intake of 335 
moxifloxacin. The default two compartment models already included Tlag. The final models of MFX and 336 
MFX+RIF were chosen based on AIC values.  337 
The final models were internally validated using 11 different (n-7) sub models for MFX and 12 (n-2) sub 338 
models for MFX+RIF, each leaving out randomly chosen pharmacokinetic curves. All pharmacokinetic 339 
curves were excluded once (jackknife analysis). The Bayesian fitted AUC0-24 of each left out curve (AUC0-24, 340 













plot and Passing Bablok regression (Analyse-it 4.81, Analyse-it Software Ltd, Leeds, United Kingdom). In 342 
the calculation of AUC0-24, ref, moxifloxacin concentrations at t=0 and 24 h after drug intake were assumed 343 
to be equal due to steady state conditions. Cmax (mg/L) was defined as the highest observed moxifloxacin 344 
concentration and Tmax (h) as the time at which Cmax occurred. Non-compartmental parameters (AUC0-24, 345 
ref, dose-corrected AUC0-24, ref to the standard dose of 400 mg, Cmax, Tmax) and population pharmacokinetic 346 
model parameters of the MFX and MFX+RIF group were compared and tested for significant differences 347 
using the Mann-Whitney U test. 348 
 349 
LSS using Bayesian approach 350 
Using the Bayesian approach, we performed two separate analyses to develop LSSs; one for MFX and 351 
one for MFX+RIF. Using Monte Carlo simulation in MWPharm, 1000 virtual pharmacokinetic profiles 352 
were created to represent the pharmacokinetic data used in the development of the LSS. The reference 353 
patient for the Monte Carlo simulation was selected based on representative pharmacokinetic data and 354 
patient characteristics. For MFX, a 36 year old male with a bodyweight of 57 kg, height of 1.60 m, BMI of 355 
22.2 kg/m2, serum creatinine of 74 µmol/L, and moxifloxacin dose of 7.0 mg/kg was chosen. For 356 
MFX+RIF, a 56 year old male with a bodyweight of 56 kg, height of 1.63 m, BMI of 21.1 kg/m2, serum 357 
creatinine of 80 µmol/L, and moxifloxacin dose of 7.1 mg/kg was selected. The LSSs were optimised using 358 
the steady state AUC0-24. Only clinically feasible LSSs using 1-3 samples between 0 and 6 h post-dose and 359 
sample interval of 1 h were tested. The LSSs were evaluated using acceptance criteria for precision and 360 
bias (RMSE<15%, MPE<5%).(18) For both MFX and MFX+RIF, one LSS was chosen for internal validation 361 
based on performance as well as clinical feasibility. The AUC0-24 estimated with the chosen LSS (AUC0-24, 362 
est) was compared with AUC0-24, ref using a Bland-Altman plot and Passing Bablok regression. Additionally, 363 
the performance of a LSS using 2 and 6 h post-dose samples was evaluated, because this is a LSS 364 














LSS using multiple linear regression 367 
Two separate analyses (MFX and MFX+RIF) using multiple linear regression were performed.  368 
Only clinically suitable LSSs (1-3 samples, 0-6 h post-dose, sample interval 1 h) were included in the 369 
analysis. Each analysis excluded the pharmacokinetic curves without data at the selected time points of 370 
the LSS, resulting in a variable number of included curves (N). Multiple linear regression in Microsoft 371 
Office Excel 2010 was used to evaluate the correlation of moxifloxacin concentrations at the chosen time 372 
points of the LSS and AUC0-24, ref. The acceptance criteria (RMSE<15%, MPE<5%) were applied to each 373 
LSS.(18) Internal validation using 11 different (n-6) sub analyses for MFX and 14 (n-1) sub analyses for 374 
MFX+RIF was used to evaluate the performance of the LSSs. Each sub analysis excluded randomly chosen 375 
profiles and all profiles were excluded once (jackknife analysis). Agreement of AUC0-24, est and AUC0-24, ref 376 
was tested using a Bland-Altman plot and Passing Bablok regression. 377 
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Table 1. Patient characteristics of the study population. Data is presented as median (IQR) unless 513 





P value  
Male sex [n(%)] 47 (61.0) 21 (87.5) 0.023a 
Age (yr) 33 (25-41) 48 (36-62) <0.001b 
Ht (m) 1.65 (1.59-1.74) 1.72 (1.64-1.76) 0.047b 
Wt (kg) 58.0 (52.5-68.2) 55.5 (52.3-63.9) 0.500b 
Dose (mg/kg bodywt) 7.0 (5.9-8.1) 7.3 (6.4-7.7) 0.629b 
BMI (kg/m2) 21.2 (19.3-23.5) 20.1 (17.6-22.7) 0.053b 
Serum creatinine (µmol/L) 71 (59-83) 73 (63-91) 0.752b 
Number of samples per 
curve 
7 (6-8) 10 (7-10) <0.001b 
Days on rifampicin 
treatment at time of 
sampling 
NA 35 (13-87) NA 
a Fisher exact test 515 














Table 2. Non-compartmental parameters (AUC0-24, ref, dose corrected AUC0-24, ref to 400 mg standard dose, 518 
Cmax, and Tmax) of MFX and MFX+RIF, presented as median (IQR). 519 
Parameter MFX (n=77) MFX+RIF (n=24) P-value 
AUC0-24, ref (mg∙h/L) 34.0 (25.2-49.2) 25.5 (20.4-31.6) 0.006
a 
Dose corrected AUC0-24, ref 
(mg∙h/L, per 400 mg) 
30.8 (24.7-40.3) 25.5 (19.1-31.3) 0.014a 
Cmax (mg/L) 3.00 (2.27-4.64) 2.83 (2.25-3.90) 0.407
a 
Tmax (h) 2 (1-3) 1.5 (1-2) 0.018
a 
a Mann-Whitney U test 520 
Table 3. Starting parameters of the default one compartment and two compartment models of MFX and 521 












CL (L/h) 18.500±8.600 14.655±5.683 18.500±8.600 19.898±8.800 
Vd (L/kg bodyweight) 3.000±0.7000 2.7467±1.0077 3.000±0.7000 2.8264±0.6902 
Ka (/h) 1.1500±1.1600 6.2904±4.8164 1.1500±1.1600 7.3755±6.8205 
Tlag (h) NA 0.8769±0.2357 NA 0.7460±0.1093 
AIC 5564 903 1361 236 
Two compartments 
CL (L/h) 11.800±0.740 13.428±5.494 49.100±2.550 18.108±8.570 
CL12 (L/h) 5.620±1.080 5.620±1.080 3.150±0.800 3.150±0.800 













V2 (L/kg bodyweight) 0.6900±0.1300 0.6900±0.1300 0.8900±0.1900 0.8900±0.1900 
Ka (/h) 16.7000±2.9200 3.2774±2.9422 2.3200±0.5600 6.2314±9.0508 
Tlag (h) 0.4600±0.0800 0.7940±0.3720 0.6000±0.0700 0.7312±0.1995 
AIC 11892 940  2995 249 
 523 
Table 4. Comparison of pharmacokinetic parameters of the population pharmacokinetic model of MFX 524 
versus MFX+RIF. Geometric mean±SD. 525 
Parameter MFX (n=77) MFX+RIF (n=24) P value 
CL/F (L/h) 14.655±5.683 19.898±8.800 0.004a 
Vd/F (L/kg bodyweight) 2.7467±1.0077 2.8264±0.6902 0.534
a 
Ka (/h) 6.2904±4.8164 7.3755±6.8205 0.231
a 
Tlag (h) 0.8769±0.2357 0.7460±0.1093 <0.001
a 
a Mann-Whitney U test 526 
 527 
Table 5. LSSs of moxifloxacin without RIF using the Bayesian approach, including MPE, RMSE, and r2. 528 
Sampling time 
point (h) 
MPE (%) RMSE (%) r2 
5   2.69 24.64 0.659 
6   1.74 22.00 0.726 
2 6  -2.20 20.83 0.742 
0 5  2.84 15.82 0.864 
0 6  2.42 15.17 0.874 













0 5 6 1.03 12.97 0.888 
 529 
Table 6. LSSs of moxifloxacin with RIF using the Bayesian approach, including MPE, RMSE, and r2. 530 
Sampling time 
point (h) 
MPE (%) RMSE (%) r2 
5   -1.97 22.35 0.768 
6   -0.79 19.22 0.826 
2 6  -2.89 18.38 0.832 
0 5  1.88 16.67 0.877 
0 6  2.35 15.81 0.885 
0 4 6 1.06 14.10 0.907 
0 5 6 0.79 13.73 0.912 
 531 
Table 7. LSSs of moxifloxacin without RIF using linear regression, including the equation to calculate 532 
AUC0-24, est, number of included curves (N), MPE, RMSE, and r
2. 533 
Sampling 
time point (h) 





4   AUC0-24, est= 3.47+12.32*C4 66 12.68 17.02 0.862 
6   AUC0-24, est = 2.27+15.01*C6 22 14.85 16.89 0.822 
2 6  AUC0-24, est = -1.44+3.55*C2+11.24*C6 22 10.02 12.27 0.901 
0 3  AUC0-24, est = 3.61+28.67*C0+5.38*C3 53 10.08 13.36 0.917 













0 2 4 AUC0-24, est = 1.10+20.37*C0+0.92*C2+7.71*C4 65 6.91 9.25 0.958 
0 1 4 AUC0-24, est = 1.00+21.06*C0+0.66*C1+8.02*C4 63 7.07 9.23 0.958 
a C0, C1, etc., are moxifloxacin concentrations at t=0 h, t=1 h, etc.  534 
Table 8. LSSs of MFX+RIF using multiple linear regression, including the equation to calculate AUC0-24, est, 535 
number of included curves (N), MPE, RMSE, and r2. 536 
Sampling 
time point (h) 





3   AUC0-24, est =-2.76+13.28*C3 18 8.27 11.10 0.907 
6   AUC0-24, est = 0.95+16.44*C6 16 6.93 8.87 0.941 
2 6  AUC0-24, est = 0.08+1.21*C2+15.02*C6 13 6.23 7.88 0.945 
0 6  AUC0-24, est = 1.38+7.40*C0+14.05*C6 16 5.85 6.99 0.960 
1 6  AUC0-24, est = 1.43+0.22*C1+16.25*C6 14 4.83 6.09 0.971 
0 3 6 AUC0-24, est = 1.20+10.66*C0-0.39*C3+13.52*C6 15 4.85 5.31 0.977 
0 2 6 AUC0-24, est = 0.46+9.99*C0+0.13*C2+13.39*C6 13 4.20 4.66 0.978 
a C0, C1, etc., are moxifloxacin concentrations at t=0 h, t=1 h, etc.  537 













Figure 1. Moxifloxacin concentrations of the pharmacokinetic curves of MFX (n=77) and MFX+RIF (n=24) 539 
 540 
Figure 2. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation (n-7) of 541 
population pharmacokinetic model of MFX (n=77). 542 
 543 
Figure 3. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation (n-2) of 544 
population pharmacokinetic model of MFX+RIF (n=24).  545 
 546 
Figure 4. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation of Bayesian LSS 547 
(t=0 and 6 h) of MFX (n=77). 548 
 549 
Figure 5. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation of Bayesian LSS 550 
(t=0 and 6 h) of MFX+RIF (n=24). 551 
 552 
Figure 6. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation (n-6) of LSS using 553 
multiple linear regression (t=0 and 4 h) of MFX (n=66). 554 
 555 
Figure 7. Bland-Altman plot (A) and Passing Bablok regression (B) of internal validation (n-1) of LSS using 556 
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